Ask the region’s clinical-operations leaders whether decentralised and hybrid trials are the future, and the answer is almost unanimous. Surveys keep returning the same verdict: enthusiasm is high, the patient case is compelling, and the technology is largely in hand. At West China Hospital — one of Asia’s largest trial centres — an IQVIA survey found that roughly nine in ten participants regarded decentralised participation as an acceptable way to take part in research. Industry analysts project that the global market for decentralised clinical trials (DCTs) will more than double, from around USD 9 billion in 2025 toward USD 21 billion by the early 2030s, with Asia-Pacific the fastest-growing region of all. By any reading of stated intent, the frontier should already be here.

And yet, on the ground, it is not. Despite the optimism, the published frameworks and the pilot programmes, decentralised and hybrid trials have not scaled across APAC at anything like the pace the enthusiasm implies. The dominant 2025 reality is not the fully remote trial of the conference keynote; it is selective decentralisation — a remote follow-up here, a local lab draw there, eConsent bolted onto an otherwise conventional protocol. The frontier keeps arriving in fragments. This feature examines why the gap between promise and practice persists across the region’s three most consequential DCT markets — Australia, Singapore and China — and what it would actually take to close it.

The gap nobody planned for

The enthusiasm is real and it is measurable. IQVIA’s site survey across Asia-Pacific captured broad optimism among investigators and coordinators, who pointed to lower patient burden, better trial continuity and more inclusive recruitment as the tangible benefits of hybrid designs. Speaking to BioPharma APAC, IQVIA’s regional clinical-development and DCT-deployment leads framed APAC as a prime location for trials precisely because of its large, ethnically diverse patient pool — while cautioning that the region is not one market but many, spanning healthcare systems of wildly different maturity, funding and digital readiness. That single observation contains most of the puzzle.

On paper, the demand signals could hardly be stronger. One regional market analysis estimates that a majority of future trials in APAC will incorporate decentralised elements, against a clinical-trials market already worth tens of billions of dollars. Oncology, with its long monitoring tails and frail patients, leads therapeutic uptake worldwide. Telehealth infrastructure — the precondition for any remote model — has scaled dramatically across the region; India’s national telemedicine service alone has logged hundreds of millions of consultations. The ingredients for adoption are demonstrably present.

The disappointment lives in the conversion. High stated interest has translated into modest, piecemeal adoption: hybrid pilots that prove the concept and then stall before they become the default operating model. The teams doing it well, the 2025 evidence suggests, treat decentralisation as an operational redesign rather than a technology purchase — aligning remote elements with the same oversight discipline as a site-based trial. The teams doing it badly simply add apps and confusion on top of an already overloaded coordinator. But even the disciplined adopters hit a ceiling that no amount of good project management dissolves: the ceiling is regulatory and jurisdictional, and it is the subject of the rest of this piece.

Talk to the people who actually run these studies and the diagnosis sharpens. A CRO decentralised-trial lead working across the region will describe the same arc again and again: a sponsor commits to a hybrid design with real conviction, the early metrics look excellent, and then the model fails to propagate to the next protocol because each new country resets the assumptions. A site investigator tells a complementary story — patients welcome fewer clinic visits, frail and rural participants who would never have enrolled in a site-bound study suddenly can, yet the coordinator’s workload balloons unless the remote components are genuinely integrated rather than stapled on. These are not technology complaints. They are the friction of running a borderless model inside bordered systems.

The recruitment and retention numbers are what make the stalled adoption so frustrating. Where decentralised designs are executed well, the deltas are striking: the Singapore PROMOTE study’s roughly 97 per cent retention sits well above the attrition many site-based trials quietly absorb, and decentralised models repeatedly show lower screen-failure rates and fewer missed visits because participation bends around the patient’s life rather than the reverse. Inclusivity improves too — the model reaches populations that geography or mobility would otherwise exclude. When the upside is this legible, the question is no longer whether DCTs work, but why a method that demonstrably improves the metrics sponsors are judged on has not become the default.

“These are not technology complaints. They are the friction of running a borderless model inside bordered systems.”

Three regulators, three philosophies

Nothing illustrates APAC’s fragmentation better than placing its leading DCT jurisdictions side by side. Australia, Singapore and China each profess support for patient-centric, technology-enabled research — and each has arrived at a markedly different regulatory posture. A sponsor designing one regional protocol must, in effect, design three.

Australia has gone furthest in building decentralisation into national infrastructure. Its Australasian Teletrial Model was created expressly to bring trials “closer to home” for rural and regional patients, and the federally funded Teletrial Programme has been extending that model across the states and territories since 2020, supported by national standard operating procedures that explicitly cover teletrials. In May 2024 the government committed fresh funding to a National One Stop Shop intended to harmonise and nationalise trial administration — folding notification, approval, safety reporting and good-clinical-practice inspection into a single platform. Australia’s adoption of ICH E6(R3), effective from January 2026 with a one-year transition, formally writes decentralised elements into the country’s GCP expectations. The direction of travel is unambiguous: decentralisation as policy, not exception.

Singapore takes a quieter, more pragmatic route. The Health Sciences Authority regulates trials under the Health Products (Clinical Trials) Regulations and the Human Biomedical Research Act, leaning on ICH GCP rather than issuing a separate, prescriptive DCT rulebook. In practice this flexibility has enabled some of the region’s most convincing proof points. A fully decentralised randomised controlled trial run in Singapore — the PROMOTE maternal-health study — reported participant retention of around 97 per cent, high completion rates even for biological-sample collection, a better participant experience and a smaller environmental footprint than its site-based comparator. It is exactly the kind of result the enthusiasm promises; the open question is whether a single well-resourced study can be turned into a repeatable standard.

China is the most consequential market and the most cautious. Its Center for Drug Evaluation issued the country’s first dedicated DCT technical guidance in May 2024 — but deliberately scoped it to rare-disease drug development, a narrowly defined population in which to pilot the model. The guidance leans on ICH E6(R3) principles of risk-based quality management, patient-centricity and data traceability, building on a 2023 Beijing-led DCT pilot and earlier signals encouraging decentralised elements in anticancer and patient-centred trials. As of mid-2025, however, China had still issued no standalone, comprehensive guideline covering all forms of decentralised research. The intent is clear; the perimeter is small.

China’s caution is not timidity so much as sequencing. A regulator overseeing the world’s second-largest pharmaceutical market has every incentive to validate a new operating model inside a contained, lower-volume population — rare diseases — before extending it across the system. The broader policy direction is unmistakably toward digital and intelligent transformation of the entire drug value chain over the second half of this decade, and DCT elements have been seeded into anticancer, real-world-evidence and patient-centred trial guidance for years. The destination looks expansive; the on-ramp is deliberately narrow. For sponsors, that means China can be a powerful DCT market in specific indications today and a constrained one almost everywhere else — a distinction that does not travel well across a regional protocol written to a single standard.

Place the three together and the patchwork is obvious. One market treats decentralisation as national policy, one as enabling default, one as a tightly fenced pilot. For a sponsor running a multi-country APAC programme, that divergence is not a nuance — it is the difference between one protocol and three sets of assumptions about what “decentralised” is even permitted to mean.

Frameworks at a glance

The data that won’t travel

If the framework patchwork sets the ceiling, the data layer is where the real friction bites. A decentralised trial, by definition, scatters data collection across homes, local clinics, wearables and apps — and then needs to consolidate that distributed information into a single analysable dataset, often held by a sponsor headquartered on another continent. Across much of APAC, the rules are pulling in precisely the opposite direction: toward localisation, sovereignty and tightly controlled cross-border movement.

China is the sharpest case. Its Personal Information Protection Law, in force since late 2021, classifies clinical health and genetic information as sensitive personal data — and, crucially, treats the coded subject identifiers used under good clinical practice as merely de-identified, not anonymised, so the data remains in scope. Layered on top sits the Human Genetic Resources regime, under which the collection, storage, export and international sharing of human genetic material and information require administrative licensing, with such resources framed as strategic national assets. Moving trial data out of China therefore means clearing more than one gate at once.

The mechanics are unforgiving. Under the PIPL, an outbound transfer of personal information must travel one of three pathways: a security assessment led by the Cyberspace Administration of China, certification by an approved body, or a filed standard contract accompanied by a privacy-impact assessment. Sensitive personal data, or personal data above defined volume thresholds, can trigger the most demanding route; the export of human genetic resources information additionally requires national health-authority clearance. For a sponsor, a model designed to make participation effortless for patients becomes an exercise in serial regulatory clearance behind the scenes.

“A decentralised trial scatters data by design — then asks it to reassemble across borders that were built to keep it home.”

It is precisely here that programmes stall. Consider the archetypal case the region throws up repeatedly: a multinational sponsor designs a hybrid oncology study with remote symptom monitoring, home phlebotomy and centralised analytics in a hub outside the country. Sites are enthusiastic, patients are eager, the platform is validated. Then legal review surfaces the obstacle. Because the wearable and app data are sensitive personal information, and because coded identifiers leave the dataset in scope, every outbound transfer must clear a formal pathway — and any genetic component drags in a separate licensing regime on top. The remote-monitoring stream that was the protocol’s whole point becomes the element that cannot lawfully flow to where the analysis lives. The trial does not fail; it slows, re-scopes and quietly loses the efficiency advantage it was built to capture.

The fix is rarely quick. It means re-engineering data flows to process and store within the country of origin, standing up local analytics, or restructuring the study so that only permissible, aggregated outputs cross the border. Federated approaches — bringing computation to the data rather than the data to the computation — are increasingly the answer, but they demand architecture decisions made before enrolment, not after. Each option adds cost, time and complexity that erodes the very efficiency case DCTs are sold on, and each must be re-solved market by market because no two jurisdictions define the constraint identically.

There are, encouragingly, signs of pragmatism. China’s 2024 provisions on cross-border data flows eased some thresholds and exemptions, a certification route for outbound personal-information transfers took effect at the start of 2026, and a 2026 consultation draft on human-genetic-resources implementation rules has been read as a move toward a more bifurcated, transaction-friendly regime. The trajectory matters because the broader geopolitical climate is moving the other way — with tightening controls on genomic data flows between major powers adding a second, external layer of friction over and above any single country’s domestic rules.

Singapore, by contrast, offers a comparatively enabling data environment under its Personal Data Protection Act and human-biomedical-research framework — consent-heavy, particularly for human tissue, but predictable and internationally legible. Australia adds its own wrinkle: health data assets have drawn growing scrutiny under foreign-investment review, a reminder that even open-data jurisdictions increasingly treat health information as strategically sensitive. The net effect across the region is a data layer that ranges from workable to forbidding, with no common denominator a sponsor can design around once and reuse everywhere.

From pilot to standard: the operational unlock

If frameworks and data rules explain why DCTs stall, the path to scale runs through four practical levers — none of them a single technology, all of them organisational.

Local expertise, not imported templates. The studies that work, like Singapore’s PROMOTE trial, succeed because the decentralised infrastructure — home nursing, local sample logistics, telehealth touchpoints — is built for the local context rather than lifted from a North American playbook. APAC’s deep telehealth penetration is an asset only when paired with regionally grounded operational design and coordinators who are not simply handed more tasks. Decentralisation has to subtract burden from sites, not add it.

Streamlined, harmonised ethics review. Fragmented, sequential ethics approval across multiple sites and jurisdictions is one of the quietest killers of DCT timelines. Australia’s National One Stop Shop — consolidating notification, approval, safety reporting and inspection into one national platform — is the clearest regional template for what streamlining looks like. Single or mutually recognised ethics review, applied consistently, would remove a layer of delay that pilots can absorb but standard practice cannot.

Demonstrable technology readiness. Regulators across APAC will accept remote data capture, eConsent and wearable-derived endpoints when, and only when, the tools are validated, secure and clinically defensible — the same bar global agencies now apply. eConsent with genuine comprehension checks, audit-ready remote monitoring and traceable data lineage are no longer differentiators; they are the price of admission. Technology readiness is less about novelty than about provability.

A data architecture built for the rules. The most strategic unlock is to design the data layer for sovereignty from the outset — in-country processing, federated or local analytics, and transfer of only permissible outputs — rather than discovering the constraint after enrolment has begun. Treating cross-border data strategy as a first-order design decision, on par with the protocol itself, is what separates a programme that scales from one that pilots and stops.

None of these levers is exotic, and that is the point. The decentralised trial does not need a breakthrough technology to become standard practice in APAC; the enabling tools already exist and have been proven in the field. What it needs is alignment — between regulators who currently sit at three different points on the same spectrum, between data regimes that treat the same dataset as routine in one market and a national asset in the next, and between sponsors’ efficiency ambitions and the operational reality of building local capacity. Alignment is harder than invention, because it depends on institutions moving in concert rather than a single team executing well. But the trajectory across 2024 to 2026 — Australia’s consolidation, Singapore’s proof points, China’s cautious expansion and the first signs of pragmatism on cross-border data — suggests the pieces are edging toward each other rather than apart.

Underneath all four levers sits a workforce question. Hybrid and decentralised models demand clinical-research professionals who can manage both patient care and data beyond the four walls of a site — a capability that is scarce and unevenly distributed across the region. Building that bench is slower than buying a platform, and arguably more decisive: a sophisticated remote-monitoring stack is worthless without coordinators, home-visit nurses and data managers trained to run it to good-clinical-practice standards. The markets that invest in people, not just platforms, are the ones whose pilots will graduate.

( arcilla.fran@biopharmaapac.com )